If you’re still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed for the New York Times, you may have missed a few biomedical firsts.
This week brought the first sliver of human data from an in-body gene editing procedure, and the results were decidedly undecided (more on that below). China also continued its push in biomedicine with regulators there stamping the first approval of a drug discovered and developed in China.
Elsewhere, top biotech executives on the East and West Coasts are on the move, the Theranos saga… Read more »
UNDERWRITERS AND PARTNERS